Net Debt Summary of Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc.'s latest annual net debt in 2023 was 5.18 Million USD , down -5.96% from previous year.
Calidi Biotherapeutics, Inc.'s latest quarterly net debt in 2024 Q2 was 7.79 Million USD , down -24.57% from previous quarter.
Calidi Biotherapeutics, Inc. reported annual net debt of 5.51 Million USD in 2022, up 33.94% from previous year.
Calidi Biotherapeutics, Inc. reported annual net debt of 4.11 Million USD in 2021, down -63.56% from previous year.
Calidi Biotherapeutics, Inc. reported quarterly net debt of 10.47 Million USD for 2024 Q1, up 101.85% from previous quarter.
Calidi Biotherapeutics, Inc. reported quarterly net debt of 5.18 Million USD for 2023 Q4, up 1143.66% from previous quarter.

Annual Net Debt Chart of Calidi Biotherapeutics, Inc. (2023 - 2020)

Name	Net Debt	Net Debt Difference
AIM ImmunoTech Inc.	-4.94 Million USD	204.915%
Ampio Pharmaceuticals, Inc.	-3.81 Million USD	235.963%
Armata Pharmaceuticals, Inc.	106.84 Million USD	95.145%
Actinium Pharmaceuticals, Inc.	-74.56 Million USD	106.956%
Azitra, Inc.	-910.04 Thousand USD	669.974%
Can-Fite BioPharma Ltd.	-4.23 Million USD	222.393%
Chromocell Therapeutics Corporation	1.17 Million USD	-342.466%
CEL-SCI Corporation	9.42 Million USD	44.971%
iBio, Inc.	-9.75 Million USD	153.2%
Lineage Cell Therapeutics, Inc.	-32.49 Million USD	115.965%
MAIA Biotechnology, Inc.	-7.15 Million USD	172.538%
Matinas BioPharma Holdings, Inc.	-1.28 Million USD	504.918%
Navidea Biopharmaceuticals, Inc.	438.44 Thousand USD	-1083.047%
NovaBay Pharmaceuticals, Inc.	-390 Thousand USD	1430.0%
NanoViricides, Inc.	-4.79 Million USD	208.113%
Oragenics, Inc.	-3.17 Million USD	263.587%
BiomX Inc.	-772 Thousand USD	771.891%
BiomX Inc.	-772 Thousand USD	771.891%
Protalix BioTherapeutics, Inc.	2.64 Million USD	-95.958%
Palatin Technologies, Inc.	-8.93 Million USD	158.039%
Scorpius Holdings, Inc.	13.85 Million USD	62.568%
Theriva Biologics, Inc.	-21.02 Million USD	124.673%